Subtype
Neuroblastoma
CI-CAN-00003408Explore in graph →
137 active trials3 approved drugs27 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003408Explore in graph →
Clinical trials
616 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (80)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05650749 | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma(GPC2) | enrolling by invitation | Phase 1 | 45 | Stephan Grupp MD PhDOTHER | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07595666 | Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region. | enrolling by invitation | N/A | 1,600 | prof. dr. Koen Van LaereOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT06703944 | Risk Model for Metastasis Detection of Neuroblastoma(NB) | enrolling by invitation | — | 500 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT01868490 | The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous CIK Cells | enrolling by invitation | Phase 1 / Phase 2 | 20 | Siriraj HospitalOTHER | 1 | Feb 10, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Aug 14, 2026source: clinicaltrials